Xyratex Ltd XRTX 深 沪
等待开盘 12-03 09:30:00 美东时间
0.641
+0.029
+4.65%
华盛通- 最 高0.641
- 今 开0.6342
- 成交量 2.76万股
- 最 低 0.6265
- 昨 收 0.6125
- 总市值 370.80万
- 52周最高 1.79
- 市盈率 静 --
- 换手率 0.48%
- 52周最低 0.515
- 委 比 98.59%
- 总股本 578.47万
- 历史最高 53.01
- 量 比 0.44
- 振 幅 2.37%
- 历史最低 0.515
- 每 手 1
- 风险率 0.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Lucas GC Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket
Shares of Lucas GC Limited (NASDAQ:LGCL) rose sharply in pre-market trading aft...
11-03 18:09
XORTX Therapeutics Announces US$1.1 Million Direct Offering
XORTX Therapeutics Inc ( ($TSE:XRTX) ) has provided an update. On October 21, 2...
10-21 20:27
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) shares rose 119.1% to $9.86 during Monda...
10-21 02:39
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
XORTX Therapeutics received a notice from Nasdaq granting a 180-day extension to meet the minimum bid price requirement of US$1.00 per share by April 13, 2026. If compliance is not achieved, the company may face delisting and could appeal the decision. XORTX continues to develop therapies for gout, progressive kidney disease, and acute kidney injury.
10-21 00:34
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
XORTX Therapeutics Inc. received a notice from the Nasdaq Stock Market that its common shares fell below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has 180 days to regain compliance, during which shares will continue to trade on Nasdaq. If the bid price closes at or above $1.00 for 10 consecutive business days, the deficiency may be considered resolved. The notice does not affect the company's listing on...
10-20 22:45
Why Delcath Systems Shares Are Trading Higher By Over 14%; Here Are 20 Stocks Moving Premarket
Shares of Delcath Systems Inc (NASDAQ:DCTH) rose sharply in pre-market trading ...
10-20 17:10
XORTX Expands Kidney Disease Pipeline With $3M Acquisition Of Vectus' VB4-P5 Therapeutic Program
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney
10-17 19:10
XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
XORTX Therapeutics Inc. has entered into a binding term sheet to acquire Vectus Biosystems' Renal Anti-Fibrotic Therapeutic Program, including novel new chemical entity VB4-P5, targeting rare and prevalent kidney diseases with significant unmet needs. The program is at the pre-IND stage and backed by strong preclinical evidence and robust global patent protection. XORTX will acquire intellectual property, regulatory documentation, and manufacturi...
10-17 11:00
Join XORTX for an Exclusive Live Investor Webinar and Q&A Session on September 10
XORTX Therapeutics invites investors to a webinar on September 10, 2025, featuring CEO Dr. Allen Davidoff discussing the company's mission to develop innovative therapies for underserved cardiorenal conditions. Key programs include XRx-026 (XORLO™) for allopurinol-intolerant gout, targeting an NDA filing in early 2026, and XRx-008 for ADPKD, with孤儿药潜力。XORTX also has programs for acute kidney injury (XRx-101) and diabetic nephropathy (XRx-225). Wi...
09-04 11:00
XORTX Therapeutics Initiates IND Preparation For XRx-026, Focused On Treatment Of Gout
XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANU))), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney
09-03 19:09
